{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:05:16Z","timestamp":1787025916291,"version":"build-2736575974"},"reference-count":29,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0801","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:12:39Z","timestamp":1525237959000},"source":"Crossref","is-referenced-by-count":6,"title":["Helicobacter Pylori and Gastroduodenal Ulcer Disease"],"prefix":"10.3238","author":[{"given":"Wolfgang","family":"Fischbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bolten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Kist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"10.3238\/arztebl.2009.0801_ref1","doi-asserted-by":"crossref","unstructured":"Warren JR, Marshall BJ: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311\u20135.","DOI":"10.1016\/S0140-6736(84)91816-6"},{"key":"10.3238\/arztebl.2009.0801_ref2","doi-asserted-by":"crossref","unstructured":"Fischbach W, Malfertheiner P, Hoffmann JC, et al.: S3-Leitlinie \u201eHelicobacter pylori und gastroduodenale Ulkuskrankheit\u201c der Deutschen Gesellschaft f\u00fcr Verdauungs- und Stoffwechselkrankheiten (DGVS). In Zusammenarbeit mit der Deutschen Gesellschaft f\u00fcr Hygiene und Mikrobiologie, Gesellschaft f\u00fcr P\u00e4diatrische Gastroenterologie und Ern\u00e4hrung e.V. und der Deutschen Gesellschaft f\u00fcr Rheumatologie \u2013 AWMF-Register-Nr. 021\/001. Z Gastroenterol 2009; 47: 68\u2013102.","DOI":"10.1055\/s-0029-1237521"},{"key":"10.3238\/arztebl.2009.0801_ref3","doi-asserted-by":"crossref","unstructured":"Grimm W, Fischbach W: Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms. Dtsch Med Wochenschr 2003; 128: 1878\u201383.","DOI":"10.1055\/s-2003-42158"},{"key":"10.3238\/arztebl.2009.0801_ref4","doi-asserted-by":"crossref","unstructured":"Brenner H, Weyermann M, Rothenbacher D: Clustering of Helicobacter pylori infection in couples: differences between high- and low-prevalence population groups. Ann Epidemiol 2006; 16: 516\u201320.","DOI":"10.1016\/j.annepidem.2005.09.009"},{"key":"10.3238\/arztebl.2009.0801_ref5","unstructured":"Parsonnet J: The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 Suppl 2: 45\u201351."},{"key":"10.3238\/arztebl.2009.0801_ref6","doi-asserted-by":"crossref","unstructured":"Forman D, Newell DG, Fullerton F, et al.: Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302\u20135.","DOI":"10.1136\/bmj.302.6788.1302"},{"key":"10.3238\/arztebl.2009.0801_ref7","doi-asserted-by":"crossref","unstructured":"Parsonnet J, Hansen S, Rodriguez L, et al.: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267\u201371.","DOI":"10.1056\/NEJM199405053301803"},{"key":"10.3238\/arztebl.2009.0801_ref8","doi-asserted-by":"crossref","unstructured":"Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT: Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109: 136\u201341.","DOI":"10.1016\/0016-5085(95)90278-3"},{"key":"10.3238\/arztebl.2009.0801_ref9","unstructured":"Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F, et al.: Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996; 91: 2125\u20139."},{"key":"10.3238\/arztebl.2009.0801_ref10","doi-asserted-by":"crossref","unstructured":"Ford AC, Delaney BC, Forman D, Moayyedi P: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; (2): CD003840.","DOI":"10.1002\/14651858.CD003840.pub4"},{"key":"10.3238\/arztebl.2009.0801_ref11","doi-asserted-by":"crossref","unstructured":"Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P: A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949\u201358.","DOI":"10.1046\/j.1365-2036.2001.01109.x"},{"key":"10.3238\/arztebl.2009.0801_ref12","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, Bazzoli F, El Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772\u201381.","DOI":"10.1136\/gut.2006.101634"},{"key":"10.3238\/arztebl.2009.0801_ref13","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Layer P, Fischbach W, M\u00f6ssner J: Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Alimentary pharmacology & therapeutics 2003; 18: 615\u201325.","DOI":"10.1046\/j.1365-2036.2003.01695.x"},{"key":"10.3238\/arztebl.2009.0801_ref14","doi-asserted-by":"crossref","unstructured":"Franchini M, Criciani M, Mengoli C, et al.: Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a sytematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 237\u201346.","DOI":"10.1093\/jac\/dkm195"},{"key":"10.3238\/arztebl.2009.0801_ref15","doi-asserted-by":"crossref","unstructured":"Chen LH, Luo HS: Effects of H. pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H. pylori-positive chronic gastritis. World J Gastroenterol 2007; 13: 5380\u20133.","DOI":"10.3748\/wjg.v13.i40.5380"},{"key":"10.3238\/arztebl.2009.0801_ref16","doi-asserted-by":"crossref","unstructured":"Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M: Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34\u20137.","DOI":"10.1136\/gut.53.1.34"},{"key":"10.3238\/arztebl.2009.0801_ref17","doi-asserted-by":"crossref","unstructured":"Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al.: Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685\u20137.","DOI":"10.1136\/gut.2006.096420"},{"key":"10.3238\/arztebl.2009.0801_ref18","unstructured":"WHO\/IARC: Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177\u2013240."},{"key":"10.3238\/arztebl.2009.0801_ref19","doi-asserted-by":"crossref","unstructured":"Forman D, Graham DY: Review article: impact of Helicobacter pylori on society-role for a strategy of \u201csearch and eradicate\u201d. Aliment Pharmacol Ther 2004; 19 (Suppl1): 17\u201321.","DOI":"10.1111\/j.0953-0673.2004.01831.x"},{"key":"10.3238\/arztebl.2009.0801_ref20","doi-asserted-by":"crossref","unstructured":"Zullo A, De Francesco V, et al.: The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353\u20137.","DOI":"10.1136\/gut.2007.125658"},{"key":"10.3238\/arztebl.2009.0801_ref21","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Morena F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35\u201344.","DOI":"10.1111\/j.1365-2036.2006.02737.x"},{"key":"10.3238\/arztebl.2009.0801_ref22","doi-asserted-by":"crossref","unstructured":"Hooper L, Brown TJ, Elliott R, et al.: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948.","DOI":"10.1136\/bmj.38232.680567.EB"},{"key":"10.3238\/arztebl.2009.0801_ref23","doi-asserted-by":"crossref","unstructured":"Kearney PM, Baigent C, Godwin J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302\u20138.","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"10.3238\/arztebl.2009.0801_ref24","doi-asserted-by":"crossref","unstructured":"Fukase K, Kato M, Kikuchi A, et al.: Effect of eradication of Helicobacter pylori on the incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392\u20137.","DOI":"10.1016\/S0140-6736(08)61159-9"},{"key":"10.3238\/arztebl.2009.0801_ref25","doi-asserted-by":"crossref","unstructured":"Ho PM, Maddox TM, Wang L, et al.: Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA 2009; 301: 937\u201344.","DOI":"10.1001\/jama.2009.261"},{"key":"10.3238\/arztebl.2009.0801_ref26","doi-asserted-by":"crossref","unstructured":"Juurlink DN, Gomes T, Ko DT, et al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713\u20138.","DOI":"10.1503\/cmaj.082001"},{"key":"10.3238\/arztebl.2009.0801_ref27","doi-asserted-by":"crossref","unstructured":"Simon T, Verstuyft C, Mary-Kause M, et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363\u201375.","DOI":"10.1056\/NEJMoa0808227"},{"key":"10.3238\/arztebl.2009.0801_ref28","unstructured":"Zairis M, Patsourakos N, Makrygiannis S, et al.: The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J 2008; 29(Suppl): 134."},{"key":"10.3238\/arztebl.2009.0801_ref29","doi-asserted-by":"crossref","unstructured":"Dunn SP, Macualay TE, Brennan DM, et al.: Baseline proton pump inhibitor use is asscociated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815.","DOI":"10.1161\/circ.118.suppl_18.S_815-a"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:51:36Z","timestamp":1638852696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0801","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,4]]}}}